Articles

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Charles University, General Hospital, Prague, Czech Republic
Department of Hematology, University Hospital, Leuven, Belgium
Ernest and Helen Scott Haematological Research Institute, University of Leicester, UK
Hadassah Medical Center, Jerusalem, Israel
PA Cervello EMAT, Palermo, Italy
Hospital la Paz, Madrid, Spain
Vall d’Hebron Research Institute, Barcelona, Spain
Ohio State University, Columbus, OH, USA
Boise VA Medical Center, Boise, ID, USA
Department of Hematology and Oncology, University Hospital Brno, Czech Republic
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Wojskowy Instytut Medyczny, Warsaw, Poland
Hospital Clínico Universitario de Valencia, Health Research Institute INCLIVA, Spain
University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, UK
Fondazione Istituto Nazionale Tumori, Milan, Italy;University of Milan, Italy
Fondazione Istituto Nazionale Tumori, Milan, Italy
Lincoln, Paris, France
Sanofi R&D, Vitry sur Seine, France
Sanofi R&D, Chilly-Mazarin, France
Sanofi R&D, Vitry sur Seine, France
Fondazione Istituto Nazionale Tumori, Milan, Italy;University of Milan, Italy
Vol. 103 No. 8 (2018): August, 2018 https://doi.org/10.3324/haematol.2017.168401